GUANGDONG HYBRIBIO BIOTECH CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.13 CNY | 0.00% |
|
-2.23% | -34.37% |
| 05:53am | Hybribio Biotech Gets Patent for Spinal Muscular Atrophy Gene Kit | MT |
| May. 16 | Hybribio Biotech Unit Gets Nod to Market Deafness Gene Detection Kit in China | MT |
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company's profit outlook over the next few years is a strong asset.
- The group's high margin levels account for strong profits.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -34.37% | 545M | - | ||
| -5.27% | 12.32B | B+ | ||
| -3.86% | 8.07B | B- | ||
| +33.66% | 5.52B | C | ||
| -7.35% | 4.21B | C | ||
| -55.63% | 2.99B | D+ | ||
| +13.62% | 2.73B | - | - | |
| -3.65% | 2.43B | B- | ||
| +30.67% | 2.29B | C | ||
| -4.31% | 1.89B | D+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 300639 Stock
- Ratings Guangdong Hybribio Biotech Co.,Ltd.
